PT Medela Potentia Tbk (MDLA) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of PT Medela Potentia Tbk IDR 313, price IDR 208, upside +50.6%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PT Medela Potentia Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
17‑month range 166.83 IDR – 274.14 IDR · fair‑value band 220.80 IDR – 421.30 IDR · the 208.00 IDR price screens below the 313.23 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow PT Medela Potentia Tbk in your weekly email
Every Wednesday you see whether PT Medela Potentia Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Medela Potentia Tbk distributes and markets pharmaceutical and healthcare products, and medical devices in Indonesia and Cambodia. It also manufactures medical devices, including consumables and medical equipment for hospitals and laboratories.
Show more
PT Medela Potentia Tbk distributes and markets pharmaceutical and healthcare products, and medical devices in Indonesia and Cambodia. It also manufactures medical devices, including consumables and medical equipment for hospitals and laboratories. The company also processes medical device products; and digital platform and web portal activities for human use, as well as pharmaceutical products. In addition, the company develops GoApotik, a B2B2C platform for expanding its products to retailers, end consumers, and patients. PT Medela Potentia Tbk was founded in 2011 and is headquartered in Jakarta Selatan, Indonesia.
Stock analysis
PT Medela Potentia Tbk (MDLA) currently trades at 208.00 IDR, while our model-based Fair Value estimate is 313.23 IDR, implying the stock looks roughly 33.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 519.77 IDR per share, and 20 of the 26 models we run sit above the 208.00 IDR price.
Bear case: the Dividend Discount group reads lowest at 97.25 IDR, and 6 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 220.80 IDR (bear) to 421.30 IDR (bull), the price of 208.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
PT Medela Potentia Tbk reported revenue of 14.9T IDR in FY2025 versus 11.6T IDR in FY2021, a compound +6.4%/yr. Reported net income was 392B IDR in FY2025, compounding +4.8%/yr from FY2021.
Key figures
Market cap 2.9T IDR (≈ $163M) · P/E ratio 7.3 · P/S ratio 0.19 · EPS (TTM) 28.45 IDR · Dividend yield 4.8% · Net margin 2.6% · Return on equity 15.0% · Return on assets (EBIT) 9.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 51%, MDLA screens cheaper than that median.
Fair Value models
Bear 220.80 IDRFair Value 313.23 IDRBull 421.30 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (20.81 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.9%
Dividend (yield on the price)4.8%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 3%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −5.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside+51% · Above median
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets5% · Top 25%
Net margin (TTM)3% · Above median
Operating margin (TTM)4% · Above median
Growth and dividend
Revenue growth3% · Above median
Dividend yield (TTM)4.8% · Top 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PT Medela Potentia Tbk (MDLA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 313.23 IDR versus a price of 208.00 IDR, about +51% upside (undervalued).
What is the fair value of MDLA?
Our model-based fair value for PT Medela Potentia Tbk is 313.23 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 208.00 IDR.
What is the quality score of MDLA?
PT Medela Potentia Tbk has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Medela Potentia Tbk (MDLA)?
Our model-based price target is the fair value of 313.23 IDR (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 220.80 IDR, optimistic scenario 421.30 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Medela Potentia Tbk stock forecast for 2026?
Our models put fair value at 313.23 IDR, about +51% upside versus a price of 208.00 IDR (undervalued). Cautious scenario 220.80 IDR, optimistic scenario 421.30 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Medela Potentia Tbk (MDLA)?
PT Medela Potentia Tbk reported trailing-twelve-month revenue of about 15.0T IDR (latest available figure, as of Sep 24, 2026).
Does PT Medela Potentia Tbk pay a dividend?
PT Medela Potentia Tbk currently shows a dividend yield of about 4.76% relative to its recent price (as of Sep 24, 2026).
What growth is priced into PT Medela Potentia Tbk (MDLA)?
For today's price to be fair in a discounted-cash-flow model, PT Medela Potentia Tbk would have to grow free cash flow by -2.5 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +6.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of MDLA use?
Our models discount PT Medela Potentia Tbk at 15.0 %: a base by market capitalisation (micro), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PT Medela Potentia Tbk that is -2.5 % per year a year over ten years, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has PT Medela Potentia Tbk (MDLA) delivered so far?
Over the past 4 years revenue at PT Medela Potentia Tbk grew +6.4 % a year. The price currently implies -2.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PT Medela Potentia Tbk (MDLA) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into PT Medela Potentia Tbk (-2.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PT Medela Potentia Tbk (MDLA)?
The free-cash-flow yield on the price is 10.37 %: that much free cash flow PT Medela Potentia Tbk produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PT Medela Potentia Tbk (MDLA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Medela Potentia Tbk it is 313.23 IDR per share (as of Sep 24, 2026), against a price of 208.00 IDR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is PT Medela Potentia Tbk stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MDLA trades below its calculated fair value: price 208.00 IDR, fair value 313.23 IDR, a gap of about +51% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDLA?
No. The price is what the market pays today (208.00 IDR); the fair value is what the company's own numbers justify (313.23 IDR). For PT Medela Potentia Tbk the two are 105.23 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Medela Potentia Tbk worth?
The market values PT Medela Potentia Tbk at about 2.9T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 208.00 IDR; our models calculate a fair value of 313.23 IDR per share.
What do the bullish and bearish scenarios say about MDLA?
Our models span a range for PT Medela Potentia Tbk: cautious scenario 220.80 IDR, base 313.23 IDR, optimistic 421.30 IDR per share (as of Sep 24, 2026, price 208.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MDLA?
PT Medela Potentia Tbk trades at a price-to-earnings ratio of 7.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 313.23 IDR is built from several models across several years. Other multiples: P/B 1.0, P/S 0.2, EV/EBITDA 4.1.
How solid is the balance sheet of PT Medela Potentia Tbk (MDLA)?
Balance-sheet figures for PT Medela Potentia Tbk (as of Sep 24, 2026): return on equity 15.0%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is MDLA from its 52-week high?
PT Medela Potentia Tbk trades at 208.00 IDR, about 24% below its 52-week high of 274.14 IDR and 18% above the low of 176.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 313.23 IDR is for.
Which stocks are comparable to PT Medela Potentia Tbk?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Medela Potentia Tbk stock attractive at the current price?
The data as of Sep 24, 2026: price 208.00 IDR, calculated fair value 313.23 IDR (+51%), Quality Score 47/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDLA calculated?
We run PT Medela Potentia Tbk through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 313.23 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. PT Medela Potentia Tbk currently trades 51 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Medela Potentia Tbk (MDLA)?
The closing price on Sep 24, 2026 was 208.00 IDR. Our model-based fair value is 313.23 IDR, about +51% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Medela Potentia Tbk right now?
The price is below even our cautious bear case (220.80 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (220.80 IDR to 421.30 IDR) leaves room in how you read the outcome.
Key figures of PT Medela Potentia Tbk
How large is the market capitalisation of PT Medela Potentia Tbk (MDLA)?
The market capitalisation of PT Medela Potentia Tbk is 2.9T IDR (≈ $163M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Medela Potentia Tbk (MDLA)?
The price-to-sales ratio of PT Medela Potentia Tbk is 0.19 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PT Medela Potentia Tbk (MDLA)?
Earnings per share at PT Medela Potentia Tbk are 28.45 IDR (price ÷ EPS = P/E 7.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PT Medela Potentia Tbk (MDLA)?
The dividend yield of PT Medela Potentia Tbk is 4.8% (payout 34.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PT Medela Potentia Tbk (MDLA)?
The net margin of PT Medela Potentia Tbk is 2.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Medela Potentia Tbk (MDLA)?
The return on equity (ROE) of PT Medela Potentia Tbk is 15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Medela Potentia Tbk (MDLA)?
On an EBIT basis the return on assets of PT Medela Potentia Tbk is 9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Medela Potentia Tbk (MDLA)?
The operating margin of PT Medela Potentia Tbk is 3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Medela Potentia Tbk (MDLA)?
Revenue at PT Medela Potentia Tbk is growing +3.4% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Medela Potentia Tbk (MDLA)?
Earnings per share at PT Medela Potentia Tbk are growing −20.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does PT Medela Potentia Tbk (MDLA) hold?
PT Medela Potentia Tbk holds more cash than debt, 613B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch PT Medela Potentia Tbk in the live analysis
One click puts PT Medela Potentia Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
